Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total transaction of $87,684.02. Following the completion of the transaction, the director now directly owns 7,229,861 shares in the company, valued at approximately $55,380,735.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.82, for a total transaction of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.79, for a total transaction of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.06, for a total transaction of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.32, for a total transaction of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.30, for a total transaction of $106,457.10.
• On Tuesday, January 23rd, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.58, for a total transaction of $212,171.32.

Recursion Pharmaceuticals Stock Down 0.9 %

Recursion Pharmaceuticals stock traded down $0.07 during mid-day trading on Thursday, hitting $7.40. The company’s stock had a trading volume of 2,860,086 shares, compared to its average volume of 6,626,345. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.54 and a twelve month high of $16.75. The stock’s fifty day moving average price is $10.84 and its two-hundred day moving average price is $9.10. The stock has a market capitalization of $1.74 billion, a P/E ratio of -4.77 and a beta of 0.76.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The business had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently bought and sold shares of RXRX. Swiss National Bank raised its holdings in Recursion Pharmaceuticals by 7.6% during the first quarter. Swiss National Bank now owns 94,300 shares of the company’s stock valued at $675,000 after buying an additional 6,700 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Recursion Pharmaceuticals by 1.7% during the first quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company’s stock valued at $2,676,000 after buying an additional 6,294 shares in the last quarter. MetLife Investment Management LLC raised its holdings in Recursion Pharmaceuticals by 55.4% during the first quarter. MetLife Investment Management LLC now owns 64,035 shares of the company’s stock valued at $458,000 after buying an additional 22,833 shares in the last quarter. Rhumbline Advisers raised its holdings in Recursion Pharmaceuticals by 4.0% during the first quarter. Rhumbline Advisers now owns 123,892 shares of the company’s stock valued at $887,000 after buying an additional 4,818 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Recursion Pharmaceuticals by 8.1% during the first quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company’s stock valued at $47,338,000 after buying an additional 497,504 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

RXRX has been the topic of a number of recent analyst reports. TD Cowen initiated coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They set a “market perform” rating on the stock. KeyCorp lifted their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $12.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.